Structure-based screen identifies a potent small-molecule inhibitor of Stat5a/b with therapeutic potential for prostate cancer and chronic myeloid leukemia

Bypassing tyrosine kinases responsible for Stat5a/b phosphorylation would be advantageous for therapy development for Stat5a/b-regulated cancers. Here, we sought to identify small-molecule inhibitors of Stat5a/b for lead optimization and therapy development for prostate cancer (PC) and Bcr-Abl-drive...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Liao, Zhiyong, Gu, Lei, Vergalli, Jenny, Mariani, Samanta A., De Dominici, Marco, Lokareddy, Ravi K., Dagvadorj, Ayush, Purushottamachar, Puranik, McCue, Peter A., Trabulsi, Edouard, Lallas, Costas D., Gupta, Shilpa, Ellsworth, Elyse, Blackmon, Shauna, Ertel, Adam, Fortina, Paolo, Leiby, Benjamin, Xia, Guanjun, Rui, Hallgeir, Hoang, David T., Gomella, Leonard G., Cingolani, Gino, Njar, Vincent, Pattabiraman, Nagarajan, Calabretta, Bruno, Nevalainen, Marja T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4547362/
https://ncbi.nlm.nih.gov/pubmed/26026053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0883
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados